ResMed stock jumps 3% on RBC Capital upgrade to Outperform

ResMed shares rose 3% after RBC Capital upgraded the medical-device maker to Outperform and raised its price target to $262 from $244. RBC cited ResMed's obstructive sleep apnea leadership, with Americas Sleep device growth of 8% year over year and Rest of World growth of 13% in constant currency in fiscal Q4 2026. The analyst forecasts high-single-digit EPS growth over the next three years, while the FDA's Class I recall of React Health's Luna G3 device could further support ResMed's sleep-device momentum.

Analysis

The relevant setup is not the rating change but a potential share-gain window in a concentrated sleep-device market. If a competitor’s remediation disrupts patient resupply or DME inventory availability, ResMed can monetize the installed-base opportunity twice: initial device placement and recurring mask/accessory revenue, the latter carrying structurally higher visibility and typically better incremental economics. This should support estimates more durably than a one-quarter device shipment bump, particularly if provider switching persists after supply normalizes.

The key debate is whether the market has already capitalized a clean competitive recovery. A return of Philips capacity would likely pressure new-device pricing and sales-force intensity before it meaningfully erodes ResMed’s patient base; patients, clinicians and DMEs face switching friction once therapy is established. The more material downside is not competitor re-entry alone, but evidence that industry growth is reverting toward low-single digits while ResMed’s accessory attach rate or gross margin fails to improve—conditions that would challenge a premium multiple.

Near term, the stock can trade with defensive healthcare and rates more than fundamentals, making a broad risk-off selloff the preferable entry rather than chasing an analyst-driven move. Over the next one to three months, watch for channel checks on replacement demand, DME backlogs and mask growth; over six to eighteen months, recurring-revenue mix, gross-margin progression and capital-return cadence matter more than incremental device units. Thesis is falsified by two consecutive quarters of sub-industry device growth, material price concessions, or guidance implying mid-single-digit-or-lower EPS growth.

Key Decisions for Investors

• Accumulate RMD on market-driven weakness rather than strength, targeting entries near a 8-10% pullback from the post-upgrade level; use a 12-month horizon. Base case is multiple stability plus high-single-digit EPS compounding, with upside if competitor disruption converts into durable accessory share.
• Express relative value as long RMD / short PHG over 3-6 months, sized modestly until Philips' U.S. sleep-device commercialization timetable and pricing strategy are independently verified. The pair benefits if replacement-driven share gains prove stickier than consensus expects; exit if PHG demonstrates an earlier-than-expected, regulatory-cleared U.S. ramp.
• Do not add aggressively solely on the upgrade. Set an earnings alert: add only if Americas device growth remains above industry growth while recurring accessory metrics and gross margin confirm operating leverage; reduce if management guides to lower growth or cites broad-based pricing pressure.
• For downside control, use a break below the prior earnings-gap support level or a material cut to forward EPS expectations as a stop discipline. The principal near-term risk is valuation compression from higher real yields rather than a sudden deterioration in underlying demand.